HMA therapy for patients with myelodysplastic syndrome could potentially activate a sleeping oncogene

By | May 27, 2022
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) – a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow – and increasingly in other diseases, but their mechanism of action remains unclear.